About InterVenn
InterVenn is a Healthcare company based in San Francisco (United States) founded in 2017. InterVenn has raised $250.9 million across 6 funding rounds from investors including SoftBank Group, Genoa Ventures and Heritage Provider Network. Its chief executive, as recorded, is Andrew Quong. InterVenn offers products and services including GlycoVision and Liquid Biopsy Platform. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Gastrointestinal Cancer. Its competitors include Miroculus, Geneoscopy and AcuamarkDx; 3 of its 3 listed competitors have raised funding.
Company details
Provider of an AI-based clinical decision supporting tool for cancer detection and drug development. The company has developed tools like Dawn which is immune-oncology testing software that uses glycoproteomics and AI. The VISTA tool assists with the quantification of proteins in serum or blood. It has features to analyze clinical biomarkers for disease diagnosis, drug development, and treatment prediction. The VOCAL is a diagnostic tool for detecting cancer in ovaries.
- Headquarters San Francisco, United States
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website intervenn.com
- Social LinkedIn X
- Total Equity Funding$250.9M (USD)
in 6 rounds
- InvestorsSoftBank Group
& 10 more
Products & Services of InterVenn
InterVenn offers a comprehensive portfolio of products and services, including GlycoVision and Liquid Biopsy Platform.
Platform for analyzing glycoprotein structures in precision medicine.
Tool for detecting diseases through glycoproteome insights.
Funding Insights of InterVenn
InterVenn has successfully raised a total of $250.9M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $250.9M
- Total Rounds 6
- First Round $6.5M
(Oct 2018)
- Investors Count 11
All 6 funding rounds of InterVenn with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2022 | Series C | – | Genoa Ventures | – | |
| Aug 2021 | $201M | Series C | – | SoftBank Group, Heritage Provider Network | |
| Nov 2020 | $34M | Series B | – | – | – |
| Jul 2020 | $267,780 | Grant | – | – | |
| Dec 2018 | $9.4M | Series A | – | Genoa Ventures | |
| Oct 2018 | $6.5M | Series A | – | – | – |
11 investors in total: 11 institutional.
Investors in InterVenn
InterVenn has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include SoftBank Group, Genoa Ventures and Heritage Provider Network.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage VC firm focused on life science startups | genoavc.com | San Francisco, United States | ||
Early-stage startups are invested in by sector-agnostic VC fund. | irvinginvestors.com | New York, United States | ||
Technical founders are supported through early-stage venture capital investments. | amplifypartners.com | Menlo Park, United States | ||
Investments are made in industrial and life sciences technology companies. | anzupartners.com | Washington, Dc, United States | ||
Venture capital firm supporting AI founders through investments and community. | trueventures.com | |||
Investing in Deep Tech and emerging technologies for 12 years. | boost.vc | |||
Investments are directed toward multiple sectors via fund of funds. | 1981 | group.softbank | Minato City, Japan | |
Coordinates healthcare through medical groups in California for quality services. | 2003 | heritageprovidernetwork.com | Northridge, United States | |
Offers diversified investment management services to institutional clients. | 2015 | highsideglobal.com | Dallas, United States | |
| prado.com.sv |
Investor details for InterVenn
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of InterVenn
27 people are tracked at InterVenn (5 in leadership, 15 in board & advisors, 7 in team).
| Name | Role | Group |
|---|---|---|
Andrew Quong | President & CEO | Leadership |
Jeremy Franzen | Vice President Technology Operations / CISO | Leadership |
Ada Wong | VP, Intellectual Property | Leadership |
Rudy Peters | Senior Director, Portfolio Management Office | Leadership |
Julio Taboada | Sr Director Global Facilities, Real Estate And Lab Ops | Leadership |
Padmanee Sharma | Advisor | Board & advisors |
James Allison | Advisor | Board & advisors |
Regina Benjamin | Advisor | Board & advisors |
Arnold Levine | Advisor | Board & advisors |
Bartha Knoppers | Advisor | Board & advisors |
Edith Mitchell | Advisor | Board & advisors |
James Almas | Advisor | Board & advisors |
Carolyn Bertozzi | Co-Founder & Scientific Advisor | Board & advisors |
Evelien Dekker | Medical Advisor | Board & advisors |
Heiko Pohl | Medical Advisor | Board & advisors |
John Nik Ding | Medical Advisor | Board & advisors |
Aasma Shaukat | Medical Advisor | Board & advisors |
Heinz Läubli | Scientific Advisor | Board & advisors |
Samir Gupta | Medical Advisor | Board & advisors |
Carlito Lebrilla | Co-founder & Scientific Advisor | Board & advisors |
7 more people are available in the full profile.
Complete people profiles for InterVenn
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of InterVenn
3 dated milestones of InterVenn across 5 years, from founding to its latest funding, stage changes and deals.
- Founded InterVenn is founded.
- Funding First funding round of $6.5M.
- Funding Latest funding round, Series C,.
Competitors of InterVenn
InterVenn has 3 listed competitors in our database, 3 of them funded. They include Miroculus, Geneoscopy and AcuamarkDx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| miroculus.com | 2014 | San Francisco, United States | $48.42M | MicroRNA profiling platform is developed to detect genes in samples. | ||
| geneoscopy.com | 2015 | St. Louis, United States | $218.95M | Non-invasive biomarker tests for colorectal cancer are developed. | ||
| acuamarkdx.com | 2013 | New York, United States | $20.01M | Non-invasive screening tests for early cancer detection are provided. |
Detailed competitors of InterVenn
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of InterVenn
The website of InterVenn (intervenn.com) receives about 2.4K visits a month and ranks #7,931,813 among all websites worldwide, #7,193 in Biotechnology and Pharmaceuticals.
- Monthly visits2.4K
▲ 1.7% vs previous month
- Unique visitors1.1K
per month
- Global rank#7,931,813
among all websites
- Category rank#7,193
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.2
- Average visit13 sec
- DevicesDesktop 43% · Mobile 57%
Top companies in Oncology
3 companies that operate in the same segment as InterVenn (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Intervenn
Complete news archive for InterVenn
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InterVenn
InterVenn was founded in 2017 and raised its 1st funding round 1 year after it was founded.
InterVenn is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Andrew Quong is the CEO of InterVenn, as recorded in our data.
InterVenn is a funded company, having raised a total of $250.9M across 6 funding rounds to date. The company's 1st funding round was a Series A of $6.5M, raised on Oct 2018.
Provider of an AI-based clinical decision supporting tool for cancer detection and drug development. The company has developed tools like Dawn which is immune-oncology testing software that uses glycoproteomics and AI. The VISTA tool assists with the quantification of proteins in serum or blood. It has features to analyze clinical biomarkers for disease diagnosis, drug development, and treatment prediction. The VOCAL is a diagnostic tool for detecting cancer in ovaries.
InterVenn's top competitors include Geneoscopy, AcuamarkDx and Miroculus.
InterVenn offers GlycoVision and Liquid Biopsy Platform.
InterVenn has 11 investors. Key investors include SoftBank Group, Genoa Ventures, Heritage Provider Network, Irving Investors, and Amplify Partners.